Compare EHang Holdings Ltd - ADR (EH) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EHang Holdings Ltd - ADR vs Novo Nordisk A/S — how do they compare? EHang Holdings Ltd - ADR trades at $4.12 (market cap $309.45M), while Novo Nordisk A/S trades at $38.16 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 534.2× EHang Holdings Ltd - ADR's market cap, and Novo Nordisk A/S pays a 4.71% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 46 Days and Novo Nordisk A/S for 116 Days on average.
| EH | NVO | |
|---|---|---|
Market Cap | $309.45M | $165.31B |
Volume | 765,799 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $18.94 | $63.98 |
52-Week Low | $4.03 | $35.29 |
Typical Hold Time | 46 Days | 116 Days |
Enterprise Value | $261.14M | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $4.14, up 0.98% on the day, amid a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $275.98 million on $417.98 million revenue in 2025, with negative profit margins and ROE. Recent news includes expansion of its Global Fast Track Program to Vietnam but also multiple law firm investigations into investor claims, creating a volatile backdrop.
The outlook remains challenging due to persistent losses and regulatory scrutiny, though the company's cash position of $1.12 billion provides some buffer. Investment opportunities hinge on successful commercialization of eVTOL technology, while risks include execution missteps, intense competition, and ongoing legal probes. The stock is suitable only for high-risk investors betting on long-term AAM adoption.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
